M.D. Ph.D. Craig B. Granowitz - 28 Feb 2025 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
SVP, Chief Medical Officer
Signature
/s/ Craig B. Granowitz, M.D., Ph.D.
Issuer symbol
LXRX
Transactions as of
28 Feb 2025
Net transactions value
-$43,756
Form type
4
Filing time
03 Mar 2025, 16:31:11 UTC
Previous filing
18 Feb 2025
Next filing
17 Feb 2026
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXRX Common Stock Options Exercise +27,917 +59% 75,543 28 Feb 2025 Direct F1
transaction LXRX Common Stock Options Exercise +35,790 +47% 111,333 28 Feb 2025 Direct F1
transaction LXRX Common Stock Options Exercise +74,227 +67% 185,560 28 Feb 2025 Direct F1
transaction LXRX Common Stock Tax liability $43,756 -65,308 -35% $0.6700 120,252 28 Feb 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXRX Restricted Stock Units Options Exercise -27,917 -100% 0 28 Feb 2025 Common Stock 27,917 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -35,790 -50% 35,790 28 Feb 2025 Common Stock 35,790 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -74,227 -33% 148,453 28 Feb 2025 Common Stock 74,227 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3 Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.